LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Kislova, Maria"
  2. AU="Balducelli, Emma"
  3. AU="Mudrak, Nathan J"
  4. AU="Fagundes, Addller Oliveira"
  5. AU="Qi, Xiaoli" AU="Qi, Xiaoli"
  6. AU="Durymanov, Mikhail"
  7. AU=Yin Wenzhe
  8. AU=Vlachos Ioannis S.
  9. AU=Grundy Scott M
  10. AU="Koumoutsea, Evangelia Vlachodimitropoulou"
  11. AU="Almen, Aimee"
  12. AU="Howard, Dianna S."
  13. AU="Elizete Rizzo"
  14. AU="El Sayegh, Suzanne"
  15. AU="Vaittinen, Tiina"
  16. AU="Khir, Amir S"
  17. AU=Patterson Andrew D
  18. AU="Kim, Joyce Mary"
  19. AU="Saribay, S Adil"
  20. AU="Couderc, M."
  21. AU="Macerlane de Lira Silva"
  22. AU=Neal Michael S
  23. AU="Nakai, Kozo"
  24. AU="Debatin, Jörg F."
  25. AU="Plant, Laura"
  26. AU="Manuel Tisminetzky"
  27. AU="Monaco, Carlo"
  28. AU="Srivastava, Rupesh"
  29. AU="Nathan, Jaimie D"
  30. AU="Schnegelberger, Regina D"
  31. AU=Doshi Paresh
  32. AU="Cecilia Hognon"
  33. AU="Mason, Jeremy K."
  34. AU=Hasumi Hisashi
  35. AU="Swati Sethi"
  36. AU="Martin G. Myers, Jr."
  37. AU="Marcus-Sekura, Carol"
  38. AU="Petagine, Lucy"
  39. AU="Jessa R. Alexander"
  40. AU=Rauner Martina
  41. AU="Richlen, Mindy L"
  42. AU="Merghani, Nada M"
  43. AU=Splitt M P
  44. AU="Zlatanović, Gordana"

Suchergebnis

Treffer 1 - 7 von insgesamt 7

Suchoptionen

  1. Artikel ; Online: Significant reduction in the incidence of non-coronavirus infections in patients with chronic lymphocytic leukemia on ibrutinib and venetoclax treatment during the COVID-19 pandemic: An additional benefit of lockdown.

    Kislova, Maria / Petrenko, Andrei / Dmitrieva, Elena A / Milenkin, Alexander / Nikitin, Konstantin E / Ptushkin, Vadim V / Shabunin, Alexey V / Nikitin, Eugene A

    Hematological oncology

    2023  Band 41, Heft 4, Seite(n) 683–693

    Abstract: Effective treatment and prevention of infections challenge management of patients with chronic lymphicytic leukemia (CLL). The COVID-19 pandemic resulted in the reduction of outpatient hospital visits as a part of non-pharmaceutical interventions that ... ...

    Abstract Effective treatment and prevention of infections challenge management of patients with chronic lymphicytic leukemia (CLL). The COVID-19 pandemic resulted in the reduction of outpatient hospital visits as a part of non-pharmaceutical interventions that could affect the incidence of infectious complications. Study enrolled patients with CLL receiving ibrutinib or/and venetoclax who were observed at the Moscow City Centre of Hematology from 01 April 2017 to 31 March 2021. We found a reduction in the incidence of infectious episodes after the implementation of the lockdown in Moscow in 01 April 2020, when compared to data on the year prior to the lockdown (p < 0.0001), as well as when compared to the predictive model (p = 0.02), and based on individual infection profiles using cumulative sums (p < 0.0001). Bacterial infections had 4.44-fold decrease, bacterial in combination with undefined infections had 4.89-fold decrease, viral infections had unsignificant changes. The decrease in the number of outpatient visits coincides with the time of the lockdown could be a likely factor, explaining a decline in the incidence of infection. Patients were clustered according incidence and severity of infectious episodes for subgroup mortality assessment. No differences in overall survival due to COVID-19 were observed. Typical respiratory infections, bacterial and undefined, the transmission of which may be affected by patient-to-patient contact in the settings of out-patient health care visits were decreased, possibly due to SARS-CoV-2 restrictive measures. A positive correlation between outpatient visits and the incidence of bronchial and upper respiratory tract infection points at the role of hospital-acquired infection and attests to the necessity of reorganizing care for all patients with CLL.
    Sprache Englisch
    Erscheinungsdatum 2023-04-14
    Erscheinungsland England
    Dokumenttyp Journal Article
    ZDB-ID 604884-5
    ISSN 1099-1069 ; 0278-0232
    ISSN (online) 1099-1069
    ISSN 0278-0232
    DOI 10.1002/hon.3156
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  2. Artikel ; Online: Ibrutinib in combination with rituximab is highly effective in treatment of chronic lymphocytic leukemia patients with steroid refractory and relapsed autoimmune cytopenias.

    Nikitin, Eugene / Kislova, Maria / Morozov, Dmitry / Belyakova, Vera / Suvorova, Anna / Sveshnikova, Julia / Vyscub, Galina / Matveeva, Irina / Shirokova, Maria / Shipaeva, Anna / Klitochenko, Tatyana / Makarovskaya, Polina / Dmitrieva, Elena / Biderman, Bella / Sudarikov, Andrei / Obukhova, Tatyana / Samoilova, Olga / Kaplanov, Kamil / Konstantinova, Tatyana /
    Mayorova, Olga / Poddubnaya, Irina / Ptushkin, Vadim

    Leukemia

    2023  Band 37, Heft 7, Seite(n) 1464–1473

    Abstract: Autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) are common complications of CLL. The optimal treatment of steroid refractory AIHA/PRCA is not well established. We conducted a multicenter study of ibrutinib and rituximab in patients ... ...

    Abstract Autoimmune hemolytic anemia (AIHA) and pure red cell aplasia (PRCA) are common complications of CLL. The optimal treatment of steroid refractory AIHA/PRCA is not well established. We conducted a multicenter study of ibrutinib and rituximab in patients with relapsed/refractory to steroids AIHA/PRCA and underlying CLL. Protocol included induction (ibrutinib 420 mg/day and rituximab, 8 weekly and 4 monthly infusions) and maintenance phase with ibrutinib alone until progression or unacceptable toxicity. Fifty patients were recruited (44-warm AIHA, 2-cold AIHA, 4-PRCA). After the induction 34 patients (74%) have achieved complete response, 10 (21.7%) partial response. Median time to hemoglobin normalization was 85 days. With regards to CLL response 9 (19%) patients have achieved CR, 2 (4%) patients-stabilization and 39 (78%)-PR. The median follow-up was 37.56 months. In AIHA group 2 patients had a relapse. Among 4 patients with PRCA 1 patient did not respond, and 1 patient had a relapse after CR, 2 remained in CR. The most common adverse events were neutropenia (62%), infections (72%), gastrointestinal complications (54%). In conclusion ibrutinib in combination with rituximab is an active second-line treatment option for patients with relapsed or refractory AIHA/PRCA and underlying CLL.
    Mesh-Begriff(e) Humans ; Rituximab ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Anemia, Hemolytic, Autoimmune/drug therapy ; Anemia, Hemolytic, Autoimmune/complications ; Thrombocytopenia ; Red-Cell Aplasia, Pure ; Steroids ; Recurrence
    Chemische Substanzen Rituximab (4F4X42SYQ6) ; ibrutinib (1X70OSD4VX) ; Steroids
    Sprache Englisch
    Erscheinungsdatum 2023-05-18
    Erscheinungsland England
    Dokumenttyp Multicenter Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-023-01891-3
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  3. Artikel ; Online: COVID-19 in patients with chronic lymphocytic leukemia: a Moscow observational study.

    Kochneva, Оlga L / Kislova, Maria / Zhelnova, Evgenya I / Petrenko, Andrei A / Baryakh, Elena A / Yatskov, Konstantin V / Dmitrieva, Elena A / Misurina, Elena N / Nikitin, Konstantin E / Vasilieva, Elena J / Samsonova, Inna V / Ptushkin, Vadim V / Baranova, Ancha / Nikitin, Eugene A

    Leukemia & lymphoma

    2022  Band 63, Heft 7, Seite(n) 1607–1616

    Abstract: We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19, analyze factors associated with a severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG and IgM levels ... ...

    Abstract We describe a retrospective cohort, 156 patients with chronic lymphocytic leukemia (CLL) diagnosed with COVID-19, analyze factors associated with a severe disease course and the effects of various treatment regimens. Anti-SARS-CoV-2 IgG and IgM levels are significantly lower. Patients with CLL are more likely to have a severe course of COVID-19, with IL-6 levels acting as a consistent biomarker of disease severity. Ten patients had recurrent episodes, fatality rate of 20%. Overall survival did not differ between patients receiving ibrutinib monotherapy and anti-CD20 antibodies ± chemotherapy. It seems that the immunodeficiency inherent to CLL influences outcomes to a larger degree than does the treatment. Glucocorticoids are not associated with significant OS improvement whereas anti-cytokine compounds usage seemed to be beneficial in patients with mild pulmonary involvement. Our data attest to the necessity of reorganizing health care for patients with CLL. Early administration of effective antiviral compounds and tailored vaccination protocols are warranted.
    Mesh-Begriff(e) COVID-19/epidemiology ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/epidemiology ; Moscow ; Retrospective Studies
    Sprache Englisch
    Erscheinungsdatum 2022-02-13
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Observational Study
    ZDB-ID 1042374-6
    ISSN 1029-2403 ; 1042-8194
    ISSN (online) 1029-2403
    ISSN 1042-8194
    DOI 10.1080/10428194.2022.2034157
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  4. Artikel ; Online: Stop COVID Cohort: An Observational Study of 3480 Patients Admitted to the Sechenov University Hospital Network in Moscow City for Suspected Coronavirus Disease 2019 (COVID-19) Infection.

    Munblit, Daniel / Nekliudov, Nikita A / Bugaeva, Polina / Blyuss, Oleg / Kislova, Maria / Listovskaya, Ekaterina / Gamirova, Aysylu / Shikhaleva, Anastasia / Belyaev, Vladimir / Timashev, Peter / Warner, John O / Comberiati, Pasquale / Apfelbacher, Christian / Bezrukov, Evgenii / Politov, Mikhail E / Yavorovskiy, Andrey / Bulanova, Ekaterina / Tsareva, Natalya / Avdeev, Sergey /
    Kapustina, Valentina A / Pigolkin, Yuri I / Dankwa, Emmanuelle A / Kartsonaki, Christiana / Pritchard, Mark G / Fomin, Victor / Svistunov, Andrey A / Butnaru, Denis / Glybochko, Petr

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2020  Band 73, Heft 1, Seite(n) 1–11

    Abstract: Background: The epidemiology, clinical course, and outcomes of patients with coronavirus disease 2019 (COVID-19) in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically diagnosed COVID-19 in real- ...

    Abstract Background: The epidemiology, clinical course, and outcomes of patients with coronavirus disease 2019 (COVID-19) in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically diagnosed COVID-19 in real-life settings is lacking.
    Methods: We extracted data from the medical records of adult patients who were consecutively admitted for suspected COVID-19 infection in Moscow between 8 April and 28 May 2020.
    Results: Of the 4261 patients hospitalized for suspected COVID-19, outcomes were available for 3480 patients (median age, 56 years; interquartile range, 45-66). The most common comorbidities were hypertension, obesity, chronic cardiovascular disease, and diabetes. Half of the patients (n = 1728) had a positive reverse transcriptase-polymerase chain reaction (RT-PCR), while 1748 had a negative RT-PCR but had clinical symptoms and characteristic computed tomography signs suggestive of COVID-19. No significant differences in frequency of symptoms, laboratory test results, and risk factors for in-hospital mortality were found between those exclusively clinically diagnosed or with positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RT-PCR. In a multivariable logistic regression model the following were associated with in-hospital mortality: older age (per 1-year increase; odds ratio, 1.05; 95% confidence interval, 1.03-1.06), male sex (1.71; 1.24-2.37), chronic kidney disease (2.99; 1.89-4.64), diabetes (2.1; 1.46-2.99), chronic cardiovascular disease (1.78; 1.24-2.57), and dementia (2.73; 1.34-5.47).
    Conclusions: Age, male sex, and chronic comorbidities were risk factors for in-hospital mortality. The combination of clinical features was sufficient to diagnose COVID-19 infection, indicating that laboratory testing is not critical in real-life clinical practice.
    Mesh-Begriff(e) Adult ; Aged ; COVID-19 ; Hospitalization ; Hospitals ; Humans ; Male ; Middle Aged ; Moscow ; SARS-CoV-2
    Schlagwörter covid19
    Sprache Englisch
    Erscheinungsdatum 2020-10-06
    Erscheinungsland United States
    Dokumenttyp Journal Article ; Observational Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciaa1535
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

  5. Artikel: StopCOVID cohort: An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection

    Munblit, Daniel / Nekliudov, Nikita A / Bugaeva, Polina / Blyuss, Oleg / Kislova, Maria / Listovskaya, Ekaterina / Gamirova, Aysylu / Shikhaleva, Anastasia / Belyaev, Vladimir / Timashev, Petr / Warner, John O / Comberiati, Pasquale / Apfelbacher, Christian / Bezrukov, Evgenii / Politov, Mikhail E / Yavorovskiy, Andrey / Bulanova, Ekaterina / Tsareva, Natalya / Avdeev, Sergey /
    Kapustina, Valentina A / Pigolkin, Yuri I / Dankwa, Emmanuelle A / Kartsonaki, Christiana / Pritchard, Mark G / Victor, Fomin / Svistunov, Andrey A / Butnaru, Denis / Glybochko, Petr

    Clin. infect. dis

    Abstract: BACKGROUND: The epidemiology, clinical course, and outcomes of COVID-19 patients in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically-diagnosed COVID-19 in real-life settings is lacking. ... ...

    Abstract BACKGROUND: The epidemiology, clinical course, and outcomes of COVID-19 patients in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically-diagnosed COVID-19 in real-life settings is lacking. METHODS: We extracted data from the medical records of adult patients who were consecutively admitted for suspected COVID-19 infection in Moscow, between April 8 and May 28, 2020. RESULTS: Of the 4261 patients hospitalised for suspected COVID-19, outcomes were available for 3480 patients (median age 56 years (interquartile range 45-66). The commonest comorbidities were hypertension, obesity, chronic cardiac disease and diabetes. Half of the patients (n=1728) had a positive RT-PCR while 1748 were negative on RT-PCR but had clinical symptoms and characteristic CT signs suggestive of COVID-19 infection.No significant differences in frequency of symptoms, laboratory test results and risk factors for in-hospital mortality were found between those exclusively clinically diagnosed or with positive SARS-CoV-2 RT-PCR.In a multivariable logistic regression model the following were associated with in-hospital mortality; older age (per 1 year increase) odds ratio [OR] 1.05 (95% confidence interval (CI) 1.03 - 1.06); male sex (OR 1.71, 1.24 - 2.37); chronic kidney disease (OR 2.99, 1.89 - 4.64); diabetes (OR 2.1, 1.46 - 2.99); chronic cardiac disease (OR 1.78, 1.24 - 2.57) and dementia (OR 2.73, 1.34 - 5.47). CONCLUSIONS: Age, male sex, and chronic comorbidities were risk factors for in-hospital mortality. The combination of clinical features were sufficient to diagnoseCOVID-19 infection indicating that laboratory testing is not critical in real-life clinical practice.
    Schlagwörter covid19
    Verlag WHO
    Dokumenttyp Artikel
    Anmerkung WHO #Covidence: #840981
    Datenquelle COVID19

    Kategorien

  6. Artikel ; Online: StopCOVID cohort

    Munblit, Daniel / Nekliudov, Nikita A / Bugaeva, Polina / Blyuss, Oleg / Kislova, Maria / Listovskaya, Ekaterina / Gamirova, Aysylu / Shikhaleva, Anastasia / Belyaev, Vladimir / Timashev, Petr / Warner, John O / Comberiati, Pasquale / Apfelbacher, Christian / Bezrukov, Evgenii / Politov, Mikhail E / Yavorovskiy, Andrey / Bulanova, Ekaterina / Tsareva, Natalya / Avdeev, Sergey /
    Kapustina, Valentina A / Pigolkin, Yuri I / Dankwa, Emmanuelle A / Kartsonaki, Christiana / Pritchard, Mark G / Victor, Fomin / Svistunov, Andrey A / Butnaru, Denis / Glybochko, Petr

    Clinical Infectious Diseases ; ISSN 1058-4838 1537-6591

    An observational study of 3,480 patients admitted to the Sechenov University hospital network in Moscow city for suspected COVID-19 infection

    2020  

    Abstract: Abstract Background The epidemiology, clinical course, and outcomes of COVID-19 patients in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically-diagnosed COVID-19 in real-life settings is lacking. ...

    Abstract Abstract Background The epidemiology, clinical course, and outcomes of COVID-19 patients in the Russian population are unknown. Information on the differences between laboratory-confirmed and clinically-diagnosed COVID-19 in real-life settings is lacking. Methods We extracted data from the medical records of adult patients who were consecutively admitted for suspected COVID-19 infection in Moscow, between April 8 and May 28, 2020. Results Of the 4261 patients hospitalised for suspected COVID-19, outcomes were available for 3480 patients (median age 56 years (interquartile range 45-66). The commonest comorbidities were hypertension, obesity, chronic cardiac disease and diabetes. Half of the patients (n=1728) had a positive RT-PCR while 1748 were negative on RT-PCR but had clinical symptoms and characteristic CT signs suggestive of COVID-19 infection.No significant differences in frequency of symptoms, laboratory test results and risk factors for in-hospital mortality were found between those exclusively clinically diagnosed or with positive SARS-CoV-2 RT-PCR.In a multivariable logistic regression model the following were associated with in-hospital mortality; older age (per 1 year increase) odds ratio [OR] 1.05 (95% confidence interval (CI) 1.03 - 1.06); male sex (OR 1.71, 1.24 - 2.37); chronic kidney disease (OR 2.99, 1.89 – 4.64); diabetes (OR 2.1, 1.46 - 2.99); chronic cardiac disease (OR 1.78, 1.24 - 2.57) and dementia (OR 2.73, 1.34 – 5.47). Conclusions Age, male sex, and chronic comorbidities were risk factors for in-hospital mortality. The combination of clinical features were sufficient to diagnoseCOVID-19 infection indicating that laboratory testing is not critical in real-life clinical practice.
    Schlagwörter Microbiology (medical) ; Infectious Diseases ; covid19
    Sprache Englisch
    Verlag Oxford University Press (OUP)
    Erscheinungsland uk
    Dokumenttyp Artikel ; Online
    DOI 10.1093/cid/ciaa1535
    Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

    Zusatzmaterialien

    Kategorien

  7. Artikel ; Online: Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY.

    Chatzikonstantinou, Thomas / Scarfò, Lydia / Karakatsoulis, Georgios / Minga, Eva / Chamou, Dimitra / Iacoboni, Gloria / Kotaskova, Jana / Demosthenous, Christos / Smolej, Lukas / Mulligan, Stephen / Alcoceba, Miguel / Al-Shemari, Salem / Aurran-Schleinitz, Thérèse / Bacchiarri, Francesca / Bellido, Mar / Bijou, Fontanet / Calleja, Anne / Medina, Angeles / Khan, Mehreen Ali /
    Cassin, Ramona / Chatzileontiadou, Sofia / Collado, Rosa / Christian, Amy / Davis, Zadie / Dimou, Maria / Donaldson, David / Santos, Gimena Dos / Dreta, Barbara / Efstathopoulou, Maria / El-Ashwah, Shaimaa / Enrico, Alicia / Fresa, Alberto / Galimberti, Sara / Galitzia, Andrea / García-Serra, Rocío / Gimeno, Eva / González-Gascón-Y-Marín, Isabel / Gozzetti, Alessandro / Guarente, Valerio / Guieze, Romain / Gogia, Ajay / Gupta, Ritu / Harrop, Sean / Hatzimichael, Eleftheria / Herishanu, Yair / Hernández-Rivas, José-Ángel / Inchiappa, Luca / Jaksic, Ozren / Janssen, Susanne / Kalicińska, Elżbieta / Laribi, Kamel / Karakus, Volkan / Kater, Arnon P / Kho, Bonnie / Kislova, Maria / Konstantinou, Eliana / Koren-Michowitz, Maya / Kotsianidis, Ioannis / Kreitman, Robert J / Labrador, Jorge / Lad, Deepesh / Levin, Mark-David / Levy, Ilana / Longval, Thomas / Lopez-Garcia, Alberto / Marquet, Juan / Martin-Rodríguez, Lucia / Maynadié, Marc / Maslejova, Stanislava / Mayor-Bastida, Carlota / Mihaljevic, Biljana / Milosevic, Ivana / Miras, Fatima / Moia, Riccardo / Morawska, Marta / Murru, Roberta / Nath, Uttam Kumar / Navarro-Bailón, Almudena / Oliveira, Ana C / Olivieri, Jacopo / Oscier, David / Panovska-Stavridis, Irina / Papaioannou, Maria / Papajík, Tomas / Kubova, Zuzana / Phumphukhieo, Punyarat / Pierie, Cheyenne / Puiggros, Anna / Rani, Lata / Reda, Gianluigi / Rigolin, Gian Matteo / Ruchlemer, Rosa / Daniel de Deus Santos, Marcos / Schipani, Mattia / Schiwitza, Annett / Shen, Yandong / Simkovic, Martin / Smirnova, Svetlana / Abdelrahman Soliman, Dina Sameh / Spacek, Martin / Tadmor, Tamar / Tomic, Kristina / Tse, Eric / Vassilakopoulos, Theodoros / Visentin, Andrea / Vitale, Candida / von Tresckow, Julia / Vrachiolias, George / Vukovic, Vojin / Walewska, Renata / Wasik-Szczepanek, Ewa / Xu, Zhenshu / Yagci, Munci / Yañez, Lucrecia / Yassin, Mohamed / Zuchnicka, Jana / Angelopoulou, Maria / Antic, Darko / Biderman, Bella / Catherwood, Mark / Claus, Rainer / Coscia, Marta / Cuneo, Antonio / Demirkan, Fatih / Espinet, Blanca / Gaidano, Gianluca / Kalashnikova, Olga B / Laurenti, Luca / Nikitin, Eugene / Pangalis, Gerassimos A / Panagiotidis, Panagiotis / Popov, Viola Maria / Pospisilova, Sarka / Sportoletti, Paolo / Stavroyianni, Niki / Tam, Constantine / Trentin, Livio / Chatzidimitriou, Anastasia / Bosch, Francesc / Doubek, Michael / Ghia, Paolo / Stamatopoulos, Kostas

    EClinicalMedicine

    2023  Band 65, Seite(n) 102307

    Abstract: Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and ... ...

    Abstract Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed treatment is still unclear and represents the focus of this work.
    Methods: We conducted a retrospective international multicenter study to assess the incidence of OMs and detect potential risk factors in 19,705 patients with CLL, small lymphocytic lymphoma, or high-count CLL-like monoclonal B-cell lymphocytosis, diagnosed between 2000 and 2016. Data collection took place between October 2020 and March 2022.
    Findings: In 129,254 years of follow-up after CLL diagnosis, 3513 OMs were diagnosed (27.2 OMs/1000 person-years). The most common hematological OMs were Richter transformation, myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Non-melanoma skin (NMSC) and prostate cancers were the most common solid tumors (STs).The only predictor for MDS and AML development was treatment with fludarabine and cyclophosphamide with/without rituximab (FC ± R) (OR = 3.7; 95% CI = 2.79-4.91; p < 0.001). STs were more frequent in males and patients with unmutated immunoglobulin heavy variable genes (OR = 1.77; 95% CI = 1.49-2.11; p < 0.001/OR = 1.89; 95% CI = 1.6-2.24; p < 0.001).CLL-directed treatment was associated with non-melanoma skin and prostate cancers (OR = 1.8; 95% CI = 1.36-2.41; p < 0.001/OR = 2.11; 95% CI = 1.12-3.97; p = 0.021). In contrast, breast cancers were more frequent in untreated patients (OR = 0.17; 95% CI = 0.08-0.33; p < 0.001).Patients with CLL and an OM had inferior overall survival (OS) than those without. AML and MDS conferred the worst OS (p < 0.001).
    Interpretation: OMs in CLL impact on OS. Treatment for CLL increased the risk for AML/MDS, prostate cancer, and NMSC. FCR was associated with increased risk for AML/MDS.
    Funding: AbbVie, and EU/EFPIAInnovative Medicines Initiative Joint Undertaking HARMONY grant n° 116026.
    Sprache Englisch
    Erscheinungsdatum 2023-11-15
    Erscheinungsland England
    Dokumenttyp Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.102307
    Datenquelle MEDical Literature Analysis and Retrieval System OnLINE

    Zusatzmaterialien

    Kategorien

Zum Seitenanfang